PMC:7195088 / 5826-6230 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"155","span":{"begin":65,"end":73},"obj":"Species"},{"id":"156","span":{"begin":315,"end":323},"obj":"Species"},{"id":"190","span":{"begin":45,"end":52},"obj":"Chemical"},{"id":"191","span":{"begin":153,"end":162},"obj":"Chemical"},{"id":"192","span":{"begin":263,"end":273},"obj":"Chemical"},{"id":"215","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"216","span":{"begin":306,"end":314},"obj":"Disease"}],"attributes":[{"id":"A155","pred":"tao:has_database_id","subj":"155","obj":"Tax:9606"},{"id":"A156","pred":"tao:has_database_id","subj":"156","obj":"Tax:9606"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"MESH:C558899"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"MESH:D000069454"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:C000606551"},{"id":"A215","pred":"tao:has_database_id","subj":"215","obj":"MESH:C000657245"},{"id":"A216","pred":"tao:has_database_id","subj":"216","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"CT does not support off-label treatment with LPV/RTV in COVID-19 patients. This result should also discourage the use of other protease inhibitors (e.g. darunavir), at least until results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T24","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"T25","span":{"begin":306,"end":314},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"CT does not support off-label treatment with LPV/RTV in COVID-19 patients. This result should also discourage the use of other protease inhibitors (e.g. darunavir), at least until results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T21","span":{"begin":24,"end":29},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"CT does not support off-label treatment with LPV/RTV in COVID-19 patients. This result should also discourage the use of other protease inhibitors (e.g. darunavir), at least until results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T16","span":{"begin":24,"end":29},"obj":"Chemical"},{"id":"T17","span":{"begin":127,"end":146},"obj":"Chemical"},{"id":"T19","span":{"begin":136,"end":146},"obj":"Chemical"},{"id":"T20","span":{"begin":153,"end":162},"obj":"Chemical"},{"id":"T21","span":{"begin":263,"end":273},"obj":"Chemical"}],"attributes":[{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A18","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"CT does not support off-label treatment with LPV/RTV in COVID-19 patients. This result should also discourage the use of other protease inhibitors (e.g. darunavir), at least until results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes"}

{"project":"LitCovid-sentences","denotations":[{"id":"T42","span":{"begin":75,"end":219},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"CT does not support off-label treatment with LPV/RTV in COVID-19 patients. This result should also discourage the use of other protease inhibitors (e.g. darunavir), at least until results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes"}